Prognosis in DNA mismatch repair deficient colorectal cancer: Are all MSI tumours equivalent?

Familial Cancer

Volumn 3, Issue 2, 2004, Pages 85-91

  Clark, A J ^a   Barnetson, R ^a   Farrington, S M ^a   Dunlop, M G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Colorectal cancer; DNA mismatch repair; Genetics; Microsatellite instability; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MICROSATELLITE DNA;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; DNA DAMAGE; DNA SEQUENCE; GENE MUTATION; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HUMAN; INHERITANCE; INTERMETHOD COMPARISON; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; BASE MISPAIRING; COLORECTAL TUMOR; DNA REPAIR; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SURVIVAL;

BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA REPAIR; GERM-LINE MUTATION; HUMANS; MICROSATELLITE REPEATS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 16544371133     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:FAME.0000039915.94550.cc     Document Type: Review

References (59)

1. Halford S, Sasieni P, Rowan A et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002; 62: 53-7.
2. Laiho P, Launonen V, Lahermo P et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002; 62: 1166-70.
3. Bubb VJ, Curtis LJ, Cunningham C et al. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene 1996; %20; 12: 2641-9.
4. Forster S, Sattler HP, Hack M et al. Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. Surgery 1998; 123: 8-13.
5. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
6. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295-303.
7. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonie carcinogenesis. Nature 1993; 363: 558-61.
8. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994; 145: 148-56.
9. Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53: 5849-52.
10. Lukish JR, Muro K, DeNobile J et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 1998; 227: 51-6.
11. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-9.
12. Wright CM, Dent OF, Barker M et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87: 1197-202.
13. Curran B, Lenehan K, Mulcahy H et al. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3, N0, M0) colorectal cancer. Gut 2000; 46: 200-4.
14. Feeley KM, Fullard JF, Heneghan MA et al. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 1999; 188: 7-14.
15. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S et al. Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 1999; 19: 1821-6.
16. Ko JM, Cheung MH, Kwan MW et al. Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma. Int J Cancer 1999; %20; 84: 404-9.
17. Messerini L, Ciantelli M, Baglioni S et al. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol 1999; 30: 629-34.
18. Salahshor S, Kressner U, Fischer H et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 1999; 81: 190-3.
19. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
20. Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-7.
21. Liu B, Farrington SM, Petersen GM et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1: 348-52.
22. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455-60.
23. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-5.
24. Kuismanen SA, Holmberg MT, Salovaara R et al. Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers. Proc Natl Acad Sci USA 1999; 96: 12661-6.
25. Veigl ML, Kasturi L, Olechnowicz J et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95: 8698-702.
26. Farrington SM, Lin-Goerke J, Ling J et al. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. Am J Hum Genet 1998; 63: 749-59.
27. Farrington SM, McKinley AJ, Carothers AD et al. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer 2002; %20; 98: 844-50.
28. Liu B, Parsons R, Papadopoulos N et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996; 2: 169-74.
29. Aarnio M, Mustonen H, Mecklin JP, Jarvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med 1998; 30: 75-80.
30. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996; 78: 1149-67.
31. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110: 682-7.
32. Lin KM, Shashidharan M, Ternent CA et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 1998; 41: 428-33.
33. Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary non-polyposis colorectal cancer. Gastroenterology 2000; 118: 829-34.
34. Bertario L, Russo A, Sala P et al. Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer 1999; 80: 183-7.
35. Kee F, Collins BJ, Patterson CC. Prognosis in familial non-polyposis colorectal cancer. Gut 1991; 32: 513-6.
36. Slattery ML, Kerber RA. The impact of family history of colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol 1995; 24: 888-96.
37. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003; 39: 2142-9.
38. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996; 28: 69-85.
39. Carethers JM, Chauhan DP, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-31.
40. Kat A, Thilly WG, Fang WH et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90: 6424-8.
41. Griffin S, Branch P, Xu YZ, Karran P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 1994; 33: 4787-93.
42. Aebi S, Kurdi-Haidar B, Gordon R et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90.
43. Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-44.
44. Peters GJ, van Groeningen CJ, van der Wilt CL et al. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol 1992; 19: 26-35.
45. van Laar JA, Rustum YM, Ackland SP et al. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998; 34: 296-306.
46. Aebi S, Fink D, Gordon R et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3: 1763-7.
47. Meyers M, Wagner MW, Hwang HS et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-201.
48. Pocard M, Bras-Goncalves R, Hamelin R et al. Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status. Anticancer Res 2000; 20: 85-90.
49. Benhattar J, Cerottini JP, Saraga E et al. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69: 190-2.
50. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-44.
51. Rosty C, Chazal M, Etienne MC et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 2001; %20; 95: 162-7.
52. Liang JT, Huang KC, Lai HS et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002; %20; 101: 519-25.
53. Elsaleh H, Joseph D, Grieu F et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; %20; 355: 1745-50.
54. Hemminki A, Mecklin JP, Jarvinen H et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-8.
55. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; %19; 344: 1196-206.
56. Barratt PL, Seymour MT, Stenning SP et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360: 1381-91.
57. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
58. Carethers JM, Smith EJ, Behling CA et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
59. Iacopetta B, Elsaleh H, Zeps N. Microsatellite instability in colon cancer. N Engl J Med 2003; 349: 1774-6.